Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Labstyle Innovat (DRIO)

Labstyle Innovat (DRIO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 12,450
  • Shares Outstanding, K 43,684
  • Annual Sales, $ 7,390 K
  • Annual Income, $ -17,800 K
  • 60-Month Beta -0.18
  • Price/Sales 1.73
  • Price/Cash Flow N/A
  • Price/Book 1.82
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.56
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 11/12/19
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/18
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.43
  • Growth Rate Est. (year over year) +232,425.58%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.26 +9.62%
on 10/07/19
0.60 -52.50%
on 09/18/19
-0.12 (-28.75%)
since 09/11/19
3-Month
0.26 +9.62%
on 10/07/19
0.66 -56.57%
on 07/31/19
-0.19 (-39.36%)
since 07/11/19
52-Week
0.26 +9.62%
on 10/07/19
1.32 -78.41%
on 11/12/18
-0.61 (-67.98%)
since 10/11/18

Most Recent Stories

More News
DarioHealth CEO Erez Raphael Presents to Digital Therapeutics Leaders at DTx East 2019

DarioHealth Corp. (NASDAQ: DRIO) ("DarioHealth" or "Dario"), a leading, global digital therapeutics company, today announced that Erez Raphael, DarioHealth's Chief Executive Officer, will be a speaker...

DRIO : 0.28 (-2.46%)
DarioHealth Awarded U.S. Patent for Optical Transmission of Data Between a Sensor and Smart Device

DarioHealth Corp. ("DarioHealth" or "Dario") (Nasdaq: DRIO), a leading, global digital therapeutics company, today announced that it has received a notice of allowance from the U.S. Patent and Trademark...

DRIO : 0.28 (-2.46%)
Dance Biopharm Partners With DarioHealth to Expand Access to Digital Therapeutics Platform for Patients With Chronic Diseases

Dance Biopharm Holdings, Inc., a clinical-stage company reimagining the treatment of chronic diseases with inhaled therapies, announced today it has formed a strategic alliance with DarioHealth Corp. "Dario"...

DRIO : 0.28 (-2.46%)
DarioHealth to Present at RHK Capital Disruptive Growth Conference on Thursday, September 5th

Leading global digital therapeutics company DarioHealth Corp. (Nasdaq: DRIO) today announced that DarioHealth's Chief Executive Officer, Erez Raphael, will present to and meet with investors and analysts...

DRIO : 0.28 (-2.46%)
DarioHealth Announces Alliance with DigitalHealth.London As Part of the UK Israel Dangoor Health Initiative

DarioHealth Corp. ("DarioHealth" or "Dario") (Nasdaq: DRIO), a leading, global digital therapeutics company, today announced an alliance with DigitalHealth.London ("DH.L") as part of its UK Israel Dangoor...

DRIO : 0.28 (-2.46%)
DarioHealth Reports Results For Second Quarter 2019

-- Q2 2019 Revenue of $1.65 million, a 20% decline from Q2 2018

DRIO : 0.28 (-2.46%)
DarioHealth® Clinical Study Data Shows the Dario Membership Program Assists Diabetes Patients in Achieving Pre-Diabetic Blood-Glucose Levels and Consistent In-Range Measurements

DarioHealth Corp. (NASDAQ: DRIO) ("DarioHealth" or "Dario"), a leading global, digital therapeutics company, presented new clinical data yesterday at the American Association of Diabetes Educators ("AADE")...

DRIO : 0.28 (-2.46%)
DarioHealth to Host Second Quarter 2019 Conference Call August 13, 2019

Global digital therapeutics innovation leader DarioHealth Corp. (NASDAQ: DRIO) today announced it will release its second quarter 2019 results on Tuesday, August 13, and host a conference call the same...

DRIO : 0.28 (-2.46%)
DarioHealth to Present New Data at AADE Conference That Shows Improvement of Type 2 Diabetes Blood-glucose Levels Using MyDario(TM) App

DarioHealth Corp. (Nasdaq: DRIO) ("DarioHealth" or "Dario"), a leading global, digital therapeutics company and member of the Digital Therapeutics Alliance (DTx), today announced its plan to present the...

DRIO : 0.28 (-2.46%)
Revenues For Connected Medical Device Market Expected to Reach $6 Billion

Every day consumers become more and more connected via their smart phones and other devices for banking, entertainment and a host of other applications. Health will be one of the fastest growing sectors...

DRIO : 0.28 (-2.46%)
LVGO : 17.64 (-6.47%)
HCAT : 27.82 (+3.23%)
PHR : 27.66 (+5.41%)
MYL : 18.90 (+2.33%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More Share

Trade DRIO with:

Business Summary

DarioHealth Corp. creates mobile and digital tools. The company's product the Dario(TM) Smart Diabetes Management Solution, is a platform for diabetes management which combines blood glucose meter, native smart phone app, website portal and treatment tools to users living with diabetes, their doctors...

See More

Key Turning Points

2nd Resistance Point 0.33
1st Resistance Point 0.31
Last Price 0.28
1st Support Level 0.27
2nd Support Level 0.25

See More

52-Week High 1.32
Fibonacci 61.8% 0.92
Fibonacci 50% 0.79
Fibonacci 38.2% 0.66
Last Price 0.28
52-Week Low 0.26

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar